Insurer's foundation heart initiative addresses cardiovascular disparitiesThe Independence Blue Cross Foundation Healthy Hearts Initiative aims to improve survival rates for sudden cardiac arrest, increase CPR preparedness.
Cardiovascular drugs: Current spending, future outlookCardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.
Top 3 cardiovascular patient compliance challenges
Top 3 cardiovascular patient compliance challengesStaying compliant with a prescribed treatment regimen gives cardiovascular disease patients the best chance of improving their heart health and reducing future incidences of cardiac events. Here’s how to get patients on board.
Driving down heart disease costs: Tips for plans, providers
Driving down heart disease costs: Tips for plans, providersHeart disease takes a heavy toll on the healthcare system, but promising new treatments are emerging
Telemonitoring of heart failure patients reduces readmissionsStudy demonstrates how new technology can drive higher value healthcare for heart failure patients.
Heart drug improves life expectancyThere is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine.
Takeda announces post hoc analysis of data from EXAMINE cardiovascular safety outcomes trialIn patients with type 2 diabetes and recent acute coronary syndrome (ACS), dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin compared to placebo did not increase the risk of heart failure (HF) outcomes, according to data published in The Lancet.
Possible link between statin use and cataracts, but weigh risks and benefitsPatients taking statins may be at an increased risk for cataracts, according to a study published in the Canadian Journal of Cardiology.
[BLOG]: AHA Scientific Sessions 2014: Where do the PCSK9s fit in the post-IMPROVE-IT world? A “modest” proposalThis year, the American Heart Association (AHA) Scientific Sessions were held in Chicago, Illinois, from November 15 to 19. Of all of the late-breaking clinical trials presented at AHA 2014, the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) study of Merck’s low-density lipoprotein cholesterol (LDL-C)-reducing drugs—the statin, Zocor (simvastatin), and the fixed-dose combination, Vytorin (ezetimibe/simvastatin)—stole the show.
Aspirin: When should it be used for prevention of cardiovascular events?Physicians debated the benefits versus the risks of aspirin for cardiovascular events in an editorial published in JAMA online November 17.